News | Mammography | January 12, 2021

Therapixel receives CE mark for AI-based software MammoScreen

This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately

This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately

January 12, 2021 — Therapixel announced that MammoScreen has successfully obtained the CE mark. After having received FDA clearance for commercial sales in the United States in March 2020, this artificial intelligence (AI) solution is now available in the European market.

MammoScreen automatically analyzes screening mammograms and indicates suspicious mammograms and lesions to the radiologist. According to the probability of malignancy and the degree of confidence of the algorithm, the software assigns a unique "MammoScreen Score" ranging from 1 to 10.

A clinical study conducted in 2019 and published in Radiology: AI, showed that radiologists assisted by MammoScreen have a better performance than without the software.

MammoScreen helps to increase the interpretation speed of benign images, giving readers more time to focus on cases requiring more attention.

Already installed in 14 hospitals and radiology practices in France for clinical evaluations, MammoScreen has generated a lot of enthusiasm among radiologists. Physicians perceive it as an intuitive and easy-to-use tool that helps reassure themselves in the interpretation and avoid missing cancers.

Breast cancer is one of the most common and deadliest cancers in women worldwide, affecting 1 in 8 women in their lifetime. The earlier this disease is diagnosed, the more effective the treatment is.

"We are proud to have received the CE Mark. This brings us a step closer to our goal of reducing breast cancer burden worldwide by improving breast cancer screening," said Pierre Fillard, Therapixel's Founder and Chief Scientific Officer.

"I am confident that MammoScreen will not only increase radiologists' performance but will also improve the patient experience by reassuring women faster," stated Matthieu Leclerc-Chalvet, CEO of Therapixel.

For more information: www.mammoscreen.com

Related Content

Radiologists have recently taken on the role of activists and are tackling pressing issues in healthcare, including breast density

Getty Images

Feature | Women's Health | January 20, 2021 | By Fazila Seker, Ph.D.
Radiologists — who have long been professionals in the metaphorical and literal back-rooms of healthcare — have recen
The key trends Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Imagesbserved at 2020 Radiological Society of North America (RSNA) meeting all focused around COVID-19 (SARS-CoV-2) and the impact it has had on radiology. #RSNA #RSNA20 #RSNA2020

Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Images

Feature | RSNA | January 20, 2021 | By Melinda Taschetta-Millane and Dave Fornell
AI Metrics, LLC, a medical imaging startup focused on augmented intelligence to improve patient care, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s flagship image analysis platform.
News | Artificial Intelligence | January 18, 2021
January 18, 2021 — AI Metrics, LLC, a medical imaging startup focused on augmented intelligence to improve patient ca
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
The U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency's oversight of AI/ML-based medical software.
News | Artificial Intelligence | January 12, 2021
January 12, 2021 — The U.S.